DRUG Bright Minds Biosciences
Bright Minds Biosciences earnings company data as of 7:18 PM ET 8/21
- 1 of 1 EPS beats
History
1 period, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q2 | 14 Aug | EPS | -1.64 | -0.24 | Beat |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by DRUG's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $9.8M sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Cormorant Asset Management, LP Insider, +2 joint filersSale$9.8M 109,331 shares at $89.50 10% of stakeTraded Apr 28 Filed Apr 30
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | Period May 26, 2026 | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 424B5 | FORM 424B5 | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | Period Jan 7, 2026 | Filing Doc | |
| 6-K | Period Jan 6, 2026 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.